Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation.

Membrane transport of antisense oligonucleotides (ODN) is an inefficient process which requires special carriers for their intracellular delivery. We have developed a delivery system for AS-ODN and their phosphorothioate analogues (AS-PTO) directed against human immunodeficiency virus type 1 (HIV-1) tat mRNA for efficient transfection of HIV-1 target cells. Protamine was used to complex AS-ODN and AS-PTO to form nanoparticles with diameters of about 180 nm and surface charges in the range of -18 to +30 mV. Cellular uptake of these nanoparticles was significantly enhanced compared to naked oligonucleotides. A double labeling technique with fluorescently tagged protamine and AS-ODN was used to follow the intracellular fate of the nanoparticles. Protamine/AS-ODN nanoparticles showed release of the antisense compound leading to specific inhibition of tat mediated HIV-1 transactivation. In contrast, protamine/AS-PTO complexes were stable over 72 h, and failed to release AS-PTO. These results demonstrate that protamine/AS-ODN nanoparticles are useful for future therapeutical application to inhibit viral gene expression.

[1]  D. Conklin,et al.  Regulation of the angiotensin type-1 receptor by antisense oligonucleotides occurs through an RNase H-type mechanism. , 1999, Brain research. Molecular brain research.

[2]  C. F. Bennett,et al.  Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.

[3]  R. Balhorn,et al.  Condensation of DNA by Spermatid Basic Nuclear Proteins* , 2002, The Journal of Biological Chemistry.

[4]  G. Amidon,et al.  Enhanced cytosolic delivery of plasmid DNA by a sulfhydryl-activatable listeriolysin O/protamine conjugate utilizing cellular reducing potential , 2003, Gene Therapy.

[5]  M. Hentze,et al.  Target-specific arrest of mRNA translation by antisense 2'-O-alkyloligoribonucleotides. , 1994, Nucleic acids research.

[6]  A. Gewirtz,et al.  Nucleic acid therapeutics: a work in progress. , 2002, Current opinion in investigational drugs.

[7]  C. Leonetti,et al.  Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide. , 1999, Antisense & nucleic acid drug development.

[8]  K. C. Ting,et al.  Microparticles of poly(dl-lactic-co-glycolic acid)/poly(ethylene glycol) blends for controlled drug delivery , 1997 .

[9]  E. Lesnik,et al.  Inhibition of translation of hepatitis C virus RNA by 2-modified antisense oligonucleotides. , 1999, Antisense & nucleic acid drug development.

[10]  R. Pecora.  Dynamic Light Scattering , 1985 .

[11]  M. Wainberg,et al.  Antiviral activity and protection of cells against human immunodeficiency virus type-1 using an antisense oligodeoxyribonucleotide phosphorothioate complementary to the 5'-LTR region of the viral genome. , 1995, Gene.

[12]  Robert Gurny,et al.  Inhibition of HIV-1 in Cell Culture by Oligonucleotide-Loaded Nanoparticles , 2001, Pharmaceutical Research.

[13]  R. Stahel,et al.  Antisense oligonucleotides for cancer therapy-an overview. , 2003, Lung cancer.

[14]  T. Thomas,et al.  DNA nanoparticles and development of DNA delivery vehicles for gene therapy. , 2002, Biochemistry.

[15]  Jean-Philippe Richard,et al.  Cellular uptake and intracellular fate of antisense oligonucleotides. , 2003, Current opinion in molecular therapeutics.

[16]  V. Vlassov,et al.  Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides , 2005, Virus Genes.

[17]  R. Kozłowski,et al.  The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. , 1993, Journal of immunological methods.

[18]  E. Wickstrom,et al.  alpha-Oligodeoxynucleotide stability in serum, subcellular extracts and culture media. , 1986, Journal of biochemical and biophysical methods.

[19]  K. G. Wagner,et al.  Cooperative binding of fluorescein-labeled clupeine by DNA , 1976, Nucleic Acids Res..

[20]  B. Berne,et al.  Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics , 1976 .

[21]  Particle sizing by photon correlation spectroscopy. Part III: Mono and bimodal distributions and data analysis , 1992 .

[22]  W. J. Irwin,et al.  Biodegradable poly(L-lactic acid) matrices for the sustained delivery of antisense oligonucleotides , 1995 .

[23]  T. Antony,et al.  Laser light scattering immunoassay: an improved data analysis by CONTIN method. , 1998, Journal of biochemical and biophysical methods.

[24]  R. Pecora,et al.  Dynamic Light Scattering Measurement of Nanometer Particles in Liquids , 2000 .

[25]  R. Juliano,et al.  Cellular uptake and intracellular fate of antisense oligonucleotides. , 1992, Trends in cell biology.

[26]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001 .

[27]  S. Akhtar,et al.  Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres , 1997 .

[28]  C. Königs,et al.  Analysis of cellular factors influencing the replication of human immunodeficiency virus type I in human macrophages derived from blood of different healthy donors. , 2001, Virology.

[29]  J. H. Li,et al.  Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity. , 1996, Biochemical and molecular medicine.

[30]  R. Byrn,et al.  The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. , 1997, AIDS research and human retroviruses.

[31]  A. Zimmer,et al.  Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles. , 2001, Biochimica et biophysica acta.

[32]  L. Good,et al.  Translation repression by antisense sequences , 2003, Cellular and Molecular Life Sciences CMLS.

[33]  K S Thompson,et al.  Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems. , 2000, Journal of drug targeting.

[34]  W. J. Irwin,et al.  A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. , 1996, Molecular pharmacology.